DOCSLIB.ORG

Cphi China 2020 Exhibitor List (24-01-2020)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cphi China 2020 Exhibitor List (24-01-2020) CPhI China 2020 Exhibitor List (24-01-2020) Company Name Country Booth No. Shanghai Acebright Pharmaceuticals Group Co., Ltd. China E1H01 2Y-Chem,Ltd. China W3B32-1 3SBIOINC. China W4D02 A.H.A International Co., Ltd. China W2P02 Aarti Drugs Limited India E1D27 Aasenbo Pharma Co.,Ltd,Beijing China E3C08 Aastrid International Pvt Ltd India E1N34 ABA Chemicals (Shanghai) Limited China E3A68 Abiochem Biotechnology Co., Ltd. China W4C76 Abydos Scientific China W3C02 Accela ChemBio Co., Ltd. China E2C38 ACE Biotechnology Co., Ltd. China E5B98 Acerblend Ingredients Co.,Ltd. China W3P06 Acetar Bio-Tech Inc. China E4G15 Afine Chemicals Limited China E3C89 AG ORGANIC INC/JORYHERB LTD China E5D32 Agno Pharma UNITED STATES TBC AH BIOPHARM CO.,LTD China W3B32-30 Akin Chemicals,Inc.(SiChuan) China E5B31 Alchem International Pvt Ltd India E1D36 AlgaNovo International Co., Ltd. China E5D35 Alkaloids Corporation India E1E51 Allychem Co., Ltd. China W4P10 ALP Pharm Beijing Co., Ltd. China E7A62 ALT Laboratory Limited China W1A38b AMAL BIOCARE Co.,Ltd China E7E07 Amano Enzyme China Ltd China E1B15 Ami Lifesciences Pvt Ltd India E2B79 Amicogen (China) Biopharm Co., Ltd China E2A28 Amphaster Nanjin Pharmaceuticals Inc China E2P10 AMRI UNITED STATES TBC Angel Yeast Co.,Ltd. China E3B76 Anhui (Shanghai）Eastmark International Trading Co., Ltd. China E6E31 Anhui Anke Biotechnology (Group) Co., Ltd. China W3C20 Anhui Ante Food Co.,Ltd. China E3G02 Anhui Bayi Chemical Industry Co., Ltd. China E7E57 Anhui BBCA Pharmaceutical Co., Ltd. China E6A02 Anhui Biochem United Pharmaceutical Co.,Ltd. China E1K18 Anhui Changjiang Pharmaceutical Co.,Ltd China E3A32 Anhui Chem-Bright Bioengineering Co., Ltd China E5E49 Anhui Dexinjia Biopharm Co., Ltd. China W4C36 Anhui GSH Bio-Technology CO.,LTD China W4P28 Anhui Guangxin Agrochemical Co.,Ltd China E6Q12 Anhui Haikang Pharmaceutical Co., Ltd. China E2E12e Anhui Hailan Bio-technology Co.,Ltd. China E3E72 ANHUI HEGENG BIOTECH ENGINEERING CO.,LTD China E5F27 Anhui Heryi Pharmaceutical Co.,Ltd. China W7A30 Anhui HuaHeng Biotechnology Co., Ltd. China E6A50 ANHUI JINBANG MEDICINE CHEMICAL CO.,LTD China E7B20 ANHUI JINDING PHARMACEUTICAL CO.,LTD China E7A78 #Information Classification: General Anhui Jinhe Industrial Co., Ltd China E6E02 ANHUI JINQUAN BIOLOGICAL TECHNOLOGY CO.,LTD. China W2G21a Anhui Lianchuang Biological Medicine Co., Ltd. China E6E07 Anhui Liangchen Silicon Material Co., Ltd China E3G16 ANHUI LIXING CHEMICAL CO., LTD. China E6F20 Anhui Pioneer Pharmaceutical Co.,Ltd. China E3A51 ANHUI PROVINCE YIFAN SPICE CO.LTD China E5C49 Anhui Qingyun Pharmaceutical and Chemical Co., Ltd. China E6C65 Anhui Redstar Pharmaceutical Corp., Ltd China E4A71 Anhui Royal Chemical Co., Ltd. China E6D02a ANHUI RUISAI BIOCHEMICAL TECHNOLOGY CO., LTD. China E6G52 Anhui Sealong Biotechnology Co.,Ltd. China E6B58 Anhui Sholon New Material Co.,Ltd China E7C40 Anhui Sinotech industrial Co. ,Ltd. China E7D10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. China E3D46 ANHUI TIANYANG PHARMACEUTICAL CO.,LTD. China E5A58 Anhui Xingyu Chemical Co., Ltd. China W3B32-29 ANHUI XINGZHOU MEDICINE FOOD CO.,LTD China E4E56 ANHUI XINZHOU MARINE BIOLOGICAL PRODUCTS CO., LTD. China E5Q28 Anqing CHICO Pharmaceutical Co., Ltd. China E2E12b Anqing Duohui Biotechnology Co., Ltd. China W3B32-20 ANQING PHICHEM CORPORATION China W7C37 Anqiu Lu'an Pharmaceutical Co., Ltd. China W2G30 Anuh Pharma India E1A16 APC Pharmaceutical & Chemical Ltd Hong Kong E1B57 APEX HEALTHCARE LIMITED India E1M55 Arcadia Biotechnology Ltd China E4A33 Argosi International Co., Ltd. China W2G12 Argus Pharmaceuticals, Ltd. China W7C29 ARROMAX PHARMATECH CO.,LTD China W7B76 Arshine Pharmaceutical Co., Ltd. China W1C22 Arz-Greensyn Co., Ltd. China W2B20a Asia Talent Chemical Limited. China E3A52 AstaTech (Chengdu) Biopharmaceutical Corp. China W3B10 Asymchem Laboratories (Tianjin) Co., Ltd China E2B32 Atman Pharmaceuticals India E2Q12 ATTO (Chongqing)CO., LTD. China E2G83 Aurisco Pharmaceutical Co., Ltd. China W2C02 Avery Chemical (Nantong) Co., Ltd. China W3A16 AVF Chemical Industrial Co., Ltd. China W1A22 AZ PHARMACEUTICAL GROUP LIMITED China E3A36 Bachem AG SWITZERLAND TBC Baiyu PH:Rl Co., Ltd. China E3B58 BannerBio Nutraceuticals inc China E5B28 BAODING FAITHFUL INDUSTRY CO.,LTD. China E5D28 BAODING JIAHE BIO-CHEMICAL CO.,LTD. China W1B20f BAODING JIZHONG PHARMACEUTICAL CO.,LTD China E3Q10 BAODING KAIYUE CHEMICALS CO.,LTD. China E3F89 Baoji Jinsen Pharmaceutical Co., Ltd China E4F56 Baoji Kangle Bio-Tech Co., Ltd China W4G50 BASF（China）Co.,Ltd China E3E40 BAYANNUR JINSHENGHUI CHEMICALS CO., LTD China E6G70 Bayee Biotech (Anqing) Co., Ltd. China W4A80 BCN Peptides SA SPAIN TBC Beijing Beilu Pharmaceutical Co., Ltd China E3B55 #Information Classification: General Beijing Canny Consulting Inc. China W3D18 Beijing Challenge Group China E7E12 Beijing Chengzhi Life Science Co., Ltd. China E6E21 Beijing Comparison Pharmaceutical Tech. Co.,Ltd China E3A95 Beijing Fengli Jingqiu Pharmaceutical Co., Ltd. China E3F46b Beijing Geyuantianrun Bio-tech Co.,Ltd China W4D88 Beijing Gingko-Group Biological Technology Co., Ltd. China E4C20 Beijing Green Guardee Technology Co., Ltd China E7A01 Beijing Greenchem Technology Co., Ltd. China E7A16 Beijing Hope Pharmaceutical Co., Ltd. China W3E18 Beijing Huikang Boyuan Chemical Tech Co., Ltd. China W3F10 Beijing KangPuHuiWei Technology Co.,Ltd. China E7G40 Beijing Lianben Technology Development Co.,Ltd. China W3G27 Beijing Lunarsun Pharmaceutical Co., Ltd. China W3H02 Beijing Merson Pharma Co.,Ltd. China E6B80 Beijing Mesochem Technology Co., Ltd. China W4A60 Beijing odyssey chemicals Co., Ltd. China W3F31a Beijing Pure Chem.Co., Ltd. China W4B93 Beijing Ribio Biotech Co.,Ltd China E7D85 Beijing THTD Pharmaceutical Technology Co.,Ltd. China E7E71 Beijing Wisdom Chemicals Co.，LTD China W3G38 BEIJING YINGMAO PHARMACEUTICAL CO., LTD. China E3E52 Beijing Yuji Science & Technology Co.,Ltd. China E7D50 Beijing ZhongShuo Pharmaceutical Technology Development Co., Ltd. China W3B32-3 BEILITE CHEMICAL CO.,LTD China E6C62 Bekind Bioengineering Incorporated Company GD China E6G37 Bellen Chemistry Co., Ltd. China E2E37 Bengbu Huadong Bio-tech Co., Ltd China E5F42 BESTGRAND BIOTECH CO.,LTD China E4D06 Bestzyme (Shanghai) Bioengineering Co., Ltd. China W4C20 Beyron Ltd China W4A87 Bide Pharmatech Ltd. China E2E60 Binhai Golden Hilen Medicine Chemistry Co., Ltd. China W2G22 BIOBETTA PHARMACEUTICALS (SHANGHAI) CO., LTD. China E2P12 Biocompounds Pharmaceutical Inc. China W4A98 Bioiberica S.A.U. SPAIN TBC BIONNA medicine China E6B07b Biophore Pharma Inc UNITED STATES TBC Biosyn Healthy Pharma Co., Ltd. China E6A41 Biosynth Carbosynth UNITED KINGDOM TBC Birdo(shanghai) Pharmatech Co.,Ltd China E2G38 Bloomage Biotechnology Corp., Ltd. China W1A02 BOAI NKY MEDICAL HOLDINGS LTD. China E3D02 Boeing Import & Export Ltd. China E6A31a Bontac Bio-engineering (Shenzhen) Co., Ltd. China E4F38 Boshuai Biotechnology (Tianjin) Co., Ltd China E5F40 Brenntag China E3E26 Bright Way LLC RUSSIA TBC BrightGene Bio-Medical Technology Co.,Ltd. China W2P08 BRILLIANT PHARMACEUTICAL CO.,LTD. CHENGDU China E2G22 BTC Pharmaceuticals Technology CO. LTD. China W7C39 BTP Pharmaceutical Co.,Limited China W2D28 BYN Chemical Co., Ltd. China W4B76 C&J INTERNATIONAL CHEMPHARM CO.LTD. China E7E38 #Information Classification: General Canan Technique Material (Hangzhou) Inc. China E7D41 Cangzhou Enke Pharma-tech CO.,LTD China E7D98 Cangzhou Senary Chemical S.& T. Co., Ltd. China W2P20 Cangzhou Toray Fine Chemicals Co., Ltd. China E7B50 Cangzhou Lingang Xingchen Chemical Co.,Ltd. China E7B40 CAPOT CHEMICAL CO., LTD. China E7A32 Capsugel Belgium NV BELGIUM TBC CARBOGEN AMCIS AG SWITZERLAND TBC Catch Bio-science & technology Co., Ltd China E4G62 CBC (Shanghai) Trading Co., Ltd. China W3E16 CF PharmTech,Inc. China E3A56 CHANG CHUN PEOPLE PHARMACOUTICAL GROUP BIO-TECH CO.,LTD China E5B60 Changge Shengyuan Bee Industry Co.,Ltd China E5C26 Changmao Biochemical Engineering Co.,Ltd. China W4A22 Changning Youyou Bio-tech Co., Ltd. China E5G21 Changsha Heking Bio-tech Co., Ltd China E4E66 Changsha Huir Biological-Tech Co., Ltd. China E4C08 Changsha Staherb Natural Ingredients Co., Ltd. China E4D66 Changsha Zhongren Biotechnology Co.,Ltd. China E4B75 Changyi Ruihai Biological Technology Co.,Ltd China E7D59 Changzhou BOHIV Pharmaceutical Technology Co., Ltd China E7C95 Changzhou Comwin Fine Chemicals Co., Ltd. China W2C38b Changzhou Fourman Biotech Co.,Ltd China E7A21 Changzhou Golden Bright Pharmaceutical Factory China W3P01 Changzhou Huanling Chemical Co., Ltd. China E7D21 CHANGZHOU HUBIN MEDICINE RAW MATERIALS CO.,LTD China W7C51 Changzhou Keylab Biochemical Co., Ltd. China W3B32-9 Changzhou litong chem co., Ltd. China E6G22 Changzhou LonGo Chemical Co.,Ltd China E6D95 Changzhou Qianhong Bio-pharma Co., Ltd. China W2C42 CHANGZHOU REFYCHEM CO., LTD China E6Q26 Changzhou Ruiming Pharmaceuticals Co., Ltd. China W2Q02b Changzhou Sinowa Chemical Co., Ltd. China E6A21 Changzhou Siyao Pharmaceuticals Co., Ltd. China E2B20 Changzhou Sunlight Pharmaceutical Co.,Ltd. China W1H30 Changzhou United Chemical Co., Ltd. China W4B18 CHANGZHOU WELTON CHEMICAL CO., LTD China E6C53 Changzhou Yabang Pharmaceutical Co., Ltd. China W3B23a Changzhou Yabang-Qh Pharmachem Co., Ltd. China W3A20 Changzhou Yonghe Fine Chemical Co., Ltd. China E7A69 Changzhou Yuanda Pharmaceutical Chemical Co.,Ltd. China W3B26a Changzhou Idea-Works Medical Technology Co., Ltd China W4A21 ChangzhouHarvechemLtd. China E2D32b CHEDOM PHARMACEUTICAL CO.,LTD China
Load more

Recommended publications
  • World Bank Document
    CONFORMED COPY LOAN NUMBER 7909-CN Public Disclosure Authorized Project Agreement Public Disclosure Authorized (Henan Ecological Livestock Project) between INTERNATIONAL BANK FOR RECONSTRUCTION AND DEVELOPMENT Public Disclosure Authorized and HENAN PROVINCE Dated July 26, 2010 Public Disclosure Authorized PROJECT AGREEMENT AGREEMENT dated July 26, 2010, entered into between INTERNATIONAL BANK FOR RECONSTRUCTION AND DEVELOPMENT (the “Bank”) and HENAN PROVINCE (“Henan” or the “Project Implementing Entity”) (“Project Agreement”) in connection with the Loan Agreement of same date between PEOPLE’S REPUBLIC OF CHINA (“Borrower”) and the Bank (“Loan Agreement”) for the Henan Ecological Livestock Project (the “Project”). The Bank and Henan hereby agree as follows: ARTICLE I – GENERAL CONDITIONS; DEFINITIONS 1.01. The General Conditions as defined in the Appendix to the Loan Agreement constitute an integral part of this Agreement. 1.02. Unless the context requires otherwise, the capitalized terms used in the Project Agreement have the meanings ascribed to them in the Loan Agreement or the General Conditions. ARTICLE II – PROJECT 2.01. Henan declares its commitment to the objective of the Project. To this end, Henan shall: (a) carry out the Project in accordance with the provisions of Article V of the General Conditions; and (b) provide promptly as needed, the funds, facilities, services and other resources required for the Project. 2.02. Without limitation upon the provisions of Section 2.01 of this Agreement, and except as the Bank and Henan shall otherwise agree, Henan shall carry out the Project in accordance with the provisions of the Schedule to this Agreement. ARTICLE III – REPRESENTATIVE; ADDRESSES 3.01.
    [Show full text]
  • Henan Wastewater Management and Water Supply Sector Project (11 Wastewater Management and Water Supply Subprojects)
    Environmental Assessment Report Summary Environmental Impact Assessment Project Number: 34473-01 February 2006 PRC: Henan Wastewater Management and Water Supply Sector Project (11 Wastewater Management and Water Supply Subprojects) Prepared by Henan Provincial Government for the Asian Development Bank (ADB). The summary environmental impact assessment is a document of the borrower. The views expressed herein do not necessarily represent those of ADB’s Board of Directors, Management, or staff, and may be preliminary in nature. CURRENCY EQUIVALENTS (as of 02 February 2006) Currency Unit – yuan (CNY) CNY1.00 = $0.12 $1.00 = CNY8.06 The CNY exchange rate is determined by a floating exchange rate system. In this report a rate of $1.00 = CNY8.27 is used. ABBREVIATIONS ADB – Asian Development Bank BOD – biochemical oxygen demand COD – chemical oxygen demand CSC – construction supervision company DI – design institute EIA – environmental impact assessment EIRR – economic internal rate of return EMC – environmental management consultant EMP – environmental management plan EPB – environmental protection bureau GDP – gross domestic product HPG – Henan provincial government HPMO – Henan project management office HPEPB – Henan Provincial Environmental Protection Bureau HRB – Hai River Basin H2S – hydrogen sulfide IA – implementing agency LEPB – local environmental protection bureau N – nitrogen NH3 – ammonia O&G – oil and grease O&M – operation and maintenance P – phosphorus pH – factor of acidity PMO – project management office PM10 – particulate
    [Show full text]
  • 2018 Unaudited Semiannual Report
    BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) Contents Pages Management and Administration 1 Report of the Manager to the Unitholders 2 Statement of Financial Position (Unaudited) 3 Investment Portfolio (Unaudited) 4 – 5 Statement of Movements in Investment Portfolio (Unaudited) 6 – 9 SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) MANAGEMENT AND ADMINISTRATION Manager Directors of the Manager BOCOM International Asset Management Limited TAN Yueheng 9/F, Man Yee Building LI Ying 68 Des Voeux Road Central CHENG Chuange Central Hong Kong Trustee and Registrar Bank of Communications Trustee Limited 1/F, Far East Consortium Building 121 Des Voeux Road Central Central Hong Kong PRC Custodian HSBC Bank (China) Company Limited 33/F, HSBC Building, Shanghai ifc 8 Century Avenue, Pudong Shanghai Legal Counsel to the Manager Deacons 5/F, Alexandra House 18 Chater Road Central Hong Kong Auditor PricewaterhouseCoopers 21/F, Edinburgh Tower 15 Queen’s Road Central Hong Kong - 1 - SEMI-ANNUAL REPORT (UNAUDITED) FOR THE SIX MONTHS ENDED 30 JUNE 2018 BOCOM INTERNATIONAL CHINA DYNAMIC FUND (A sub-fund of BOCOM International Fund) REPORT OF THE MANAGER TO THE UNITHOLDERS The A-share market under-performance in 1H2018 can be attributed to two main factors: 1) the United States entered an interest rate hike cycle, which caused wide concern about the emerging market’s debt problems.
    [Show full text]
  • China Pharmaceutical Newsletter
    Volume VII 2011 CHINA PHARMACEUTICAL ڵNEWSLETTER З֡Ԛ哦֡ଢ଼рࡗЗ แྼჯ)ཀৄDž዆ᄱᆶ၌ࠅິ SFDA Commissioner Shao Mingli SFDA Deputy Commissioner Wu Zhen of NPC Standing Committee attended the met with new Cuban Ambassador to meets the Head of Iran's Innovation and meeting. Chen Zhu, the Health Minister China On September 29, 2011, Shao Technology Cooperation Center On the & Chairman of the Forum attended the Mingli, Commissioner of SFDA met morning of September 6, 2011, Wu Zhen, forum and delivered a speech. with Mr. ALberto Jesus Blanco Silva, the SFDA Deputy Commissioner, met with the Chen Zhu said in his speech, through new Cuban Ambassador Extraordinary visiting Mr. Hamidreza Amirinia, Head of 30 years of reform and opening up, and Plenipotentiary to China, and his Innovation and Technology Cooperation China's GDP has maintained a 10% entourage in Beijing. The two sides Center of Iran. Both parties exchanged growth in 30 consecutive years, and held in-depth discussions on further views on enhancing mutual exchanges and created an economic miracle. In 2010, strengthening the bilateral cooperation in understanding, and promoting cooperation China's GDP had ranked second in the WKH¿HOGVRIELRORJLFDl products and drug LQWKH¿HOGRIWUDGLWLRQDO&KLQHVHPHGLFLQH world. In the 21st century, the Chinese safety supervision. (September 30, 2011) and biopharmaceuticals. (September 8, 2011) Government pays more attention to social SFDA Deputy Commissioner Wu development, taking the alleviation of SFDA Deputy Commissioner Bian Zhen meets the delegation of MHLW On poverty and improvement of health care, Zhenjia attends the APEC LSIF Drug the morning of August 23, 2011, Wu Zhen, education, housing, and employment, etc.
    [Show full text]
  • Housing Vernacularism in Gaozhuang Village, Henan Prov. China
    Housing Vernacularism in Gaozhuang Village, Henan Prov. China, Towards a Promising Future A report submitted to McGill University in partial fulfillment of the requirements of the degree of Master of Architecture Jianing Gao School of Architecture McGill University Montreal, QC September 2016 Name: Jianing Gao Student ID: 260665339 Program: UDH Program Supervisor: Prof. Robert Mellin Date: Wed. September 26th, 2016 Contents Abstract Acknowledgements Chapter 1 Literature Review 1.1 Cultural Landscapes 1.2 Vernacular Architecture 1.3 Everyday Life Methodology Qualitative Study & Quantitative Study Chapter 2 Gaozhuang Village, Henan Province, China 2.1 Background 2.1.1 A Brief Introduction to Henan Province 2.1.2 A Brief Introduction to Gaozhuang Village and the Gao Family 2.2 The vernacular architecture of Henan and Gaozhuang Village 2.2.1 The development of Henan vernacular architecture 2.2.2 Vernacular architecture in Gaozhuang Village Chapter 3 Courtyard Houses in Gaozhuang Village 3.1 10 old courtyard houses——plans, sections, elevations, onsite drawings & sketches & interviews 3.2 8 semi-old courtyard houses——plans, sections, elevations, onsite drawings & sketches & interviews 3.3 12 new courtyard houses——plans, sections, elevations, onsite drawings & sketches & interviews Chapter 4 Cultual Landscape in Gaozhuang Village 4.1 Along the Yellow River... ... 4.2 The field and the working people 4.3 Fairs and markets 4.4 Everyday life---Food 4.5 Everyday life---Friendship 4.6 Everyday life---Clothing 4.7 Everyday life---Wedding ceremony 4.8 Everyday life---Entertainment Conclusion References Abstract As in many contexts, thousands of years of building houses have shaped the local features of rural houses in China in their long adaptation to nature to meet the demands of living.
    [Show full text]
  • Pharmaceuticals in China
    INDUSTRY MARKET RESEARCH FOR BUSINESS LEADERS, STRATEGISTS, DECISION MAKERS CLICK TO VIEW Table of Contents 2 List of Tables & Charts 3 Study Overview 4 Sample Text, Table & Chart 5 Sample Profile, Table & Forecast 6 Order Form 7 About Freedonia, Custom Research, Related Studies, Corporate Use License 8 Pharmaceuticals in China China Industry Study with Forecasts to 2010 & 2015 Study #2024 | February 2006 | $4800 | 240 pages The Freedonia Group 767 Beta Drive www.freedoniagroup.com Cleveland, OH • 44143-2326 • USA Toll Free US Tel: 800.927.5900 or +1 440.684.9600 Fax: +1 440.646.0484 E-mail: [email protected] Study #2024 February 2006 Pharmaceuticals in China $4800 240 Pages China Industry Study with Forecasts to 2010 & 2015 Table of Contents INTRODUCTION Shipments .......................................62 Corticosteroids ............................ 115 Types of Medicines ............................63 Estrogens & Combinations ............. 115 Astragalus ....................................64 Other Hormones ........................... 116 EXECUTIVE SUMMARY Atractylodes ..................................66 Shipments ..................................... 117 Bupleurum ....................................67 Biologicals & Vaccines ........................ 119 MARKET ENVIRONMENT China Root ....................................67 Demand ......................................... 120 General ..............................................4 Cinnamon .....................................68 Vaccines ..................................... 120
    [Show full text]
  • Henan Towns Water Supply and Sanitation Project
    Document of The World Bank Public Disclosure Authorized Report No: ICR00002898 IMPLEMENTATION COMPLETION AND RESULTS REPORT (IBRD-48290) ON A Public Disclosure Authorized LOAN IN THE AMOUNT OF US$ 150 MILLION TO THE PEOPLE’S REPUBLIC OF CHINA FOR A HENAN TOWNS WATER SUPPLY AND SANITATION PROJECT Public Disclosure Authorized December 24, 2013 Public Disclosure Authorized Sustainable Development Department China and Mongolia Country Management Unit East Asia and Pacific Region CURRENCY EQUIVALENTS Currency Unit=Renminbi (RMB) US$ 1.00 = RMB 8.0080 (Appraisal May 2006) US$ 1.00 = RMB 6.1000 (Project Closing June 2013) FISCAL YEAR January 1 – December 31 ABBREVIATIONS AND ACRONYMS ADB Asian Development Bank CPS Country Partnership Strategy CQS Consultant Quality Selection C Y Calendar Year DBO Design Build Operate EA Environmental Assessment EIA Environmental Impact Assessment EMP Environmental Management Plan EPB Environmental Protection Bureau ERR Economic Rate of Return FM Financial Management FRR Financial Rate of Return FY Fiscal Year FYP Five Year Plan GDP Gross Domestic Product GOC Government of China HPEPD Henan Provincial Environmental Protection Department HPFD Henan Provincial Financial Department IBRD International Bank for Reconstruction and Development MOF Ministry of Finance MWR Ministry of Water Resources PIU Project Implementation Unit PMO Project Management Office PPMO Provincial Project Management Office RAP Resettlement Action Plan TA Technical Assistance WTP Water Treatment Plant WUC Water Utility Company WWTP Wastewater Treatment Plant Vice President: Axel van Trotsenburg, EAPVP Country Director: Klaus Rohland, EACCF Sector Manager: Mark Lundell, EASCS Project Team Leader: Shunong Hu, EASCS ICR Team Leader: Joanna Masic, EASCS ICR Primary Author: Eddie Hum (Consultant) CHINA Henan Towns Water Supply and Sanitation Project TABLE OF CONTENTS Data Sheet A.
    [Show full text]
  • Company Report: Sinopharm
    Company Report: Sinopharm Group Co. Ltd. (01099 HK) Kay Mai 麦梓琪 公司报告：国药控股 (01099 HK) +86 755 23976685 [email protected] 国泰君安研究 2 March 2017 PRC's Largest Pharmaceutical Distributor, “Accumulate” 中国最大的医药分销商，“收集” GTJA ResearchGTJA Sinopharm is the largest pharmaceutical distributor and retailer in the Rating: Accumulate PRC, with sustainable above-industry growth. It took about 16.0% of market share in the pharmaceutical distribution industry and approximately 2.7% of market share in retail pharmacy business in 2015, according to the Ministry of 评级： 收集 Commerce in the People's Republic of China ("MOFCOM"). Sinopharm will benefit from further industry consolidation and will 6-18m TP 目标价: HK$39.89 solidify its leading position in for the foreseeable future. We believe recent polices such as the two-invoice system, unannounced Inspections, and stricter 股价： HK$36.550 Share price GSP will drive out small- and medium-sized distributors, which is likely to boost the market share and maintain the above-average growth of the Company. Revenue is estimated to grow by 12.9%, 12.8% and 12.8% YoY to Stock performance 股价表现 RMB256,337 million, RMB289,268 million and RMB326,410 million in respectively, as a result of 1) stable growth of the 50.0 % of return period FY2016-FY2018, 45.0 pharmaceutical distribution segment deriving from the combinational effect of 40.0 market share gaining growth from direct sales as well as the loss in indirect 35.0 30.0 sales triggered by industry consolidation, 2) fast expansion of the retail 25.0 business and its integration impact, and 3) a promising outlook for innovative 20.0 15.0 businesses such as financial leasing.
    [Show full text]
  • Formation of the Traditional Chinese State Ritual System of Sacrifice To
    religions Article Formation of the Traditional Chinese State Ritual System of Sacrifice to Mountain and Water Spirits Jinhua Jia 1,2 1 College of Humanities, Yangzhou University, Yangzhou 225009, China; [email protected] 2 Department of Philosophy and Religious Studies, University of Macau, Macau SAR, China Abstract: Sacrifice to mountain and water spirits was already a state ritual in the earliest dynasties of China, which later gradually formed a system of five sacred peaks, five strongholds, four seas, and four waterways, which was mainly constructed by the Confucian ritual culture. A number of modern scholars have studied the five sacred peaks from different perspectives, yielding fruitful results, but major issues are still being debated or need to be plumbed more broadly and deeply, and the whole sacrificial system has not yet drawn sufficient attention. Applying a combined approach of religious, historical, geographical, and political studies, I provide here, with new discoveries and conclusions, the first comprehensive study of the formational process of this sacrificial system and its embodied religious-political conceptions, showing how these geographical landmarks were gradually integrated with religious beliefs and ritual-political institutions to become symbols of territorial, sacred, and political legitimacy that helped to maintain the unification and government of the traditional Chinese imperium for two thousand years. A historical map of the locations of the sacrificial temples for the eighteen mountain and water spirits is appended. Keywords: five sacred peaks; five strongholds; four seas; four waterways; state ritual system of sacrifice; Chinese religion; Chinese historical geography Citation: Jia, Jinhua. 2021. Formation of the Traditional Chinese State Ritual System of Sacrifice to Mountain and Water Spirits.
    [Show full text]
  • Sinopharm Group: 2H14 NDR Takeaways: Margin Expansion To
    Sinopharm Group | March 25, 2015 MORGAN STANLEY RESEARCH March 25, 2015 MORGAN STANLEY ASIA LIMITED+ Yolanda Hu Sinopharm Group [email protected] +852 2848-5649 Bin Li 2H14 NDR Takeaways: Margin Expansion [email protected] +852 2239-7596 Isabella Zhao to Continue [email protected] +852 2848-5887 Industry View Stock Rating Price Target Attractive Overweight HK$34.00 Sinopharm Group ( 1099.HK , 1099 HK ) China Healthcare / China Stock Rating Overweight Sinopharm’s solid sales growth and operating leverage are likely to Industry View Attractive continue in 2015, despite the uncertain policy outlook for the Price target HK$34.00 Up/downside to price target (%) 15 Healthcare industry. We find the stock attractive at 18x our revised Shr price, close (Mar 24, 2015) HK$29.50 2015e EPS. Reiterate OW. 52-Week Range HK$34.50-19.72 Sh out, dil, curr (mn) 2,568 Healthy 2015 sales outlook: Given decelerating GDP growth expected in Mkt cap, curr (mn) Rmb60,695 EV, curr (mn) Rmb78,243 2015, mgmt looks for growth of the end-user market to slow to 12%, and for Avg daily trading value (mn) HK$133 the distribution industry to grow 14-15%. Management remains confident about achieving its sales target of 3-5% above the market average. Fiscal Year Ending 12/14 12/15e 12/16e 12/17e ModelWare EPS (Rmb) 1.11 1.32 1.51 1.70 Margin improvement to continue in 2015, ... This is the first quarter that Prior ModelWare EPS 1.10 1.29 1.44 1.58 (Rmb) Sinopharm has recorded faster profit growth than sales growth, mainly due to: Consensus EPS (Rmb)§ 1.10 1.30 1.55 1.50 1) internal integration; 2) economies of scale; 3) optimizing customer mix Revenue, net (Rmb 200,131 235,469 272,701 313,245 (more direct sales to hospitals), and 4) more focus on the quality of growth.
    [Show full text]
  • Announcement of Interim Results for the Six Months Ended 30 June 2021
    Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. (Stock Code: 0832) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 FINANCIAL HIGHLIGHTS • Revenue for the six months ended 30 June 2021 amounted to RMB20,357 million, an increase of 56.4% compared with the corresponding period in 2020. • Gross profit margin for the period was 17.9%, a decrease of 5.8 percentage points compared with 23.7% for the corresponding period in 2020. • Profit attributable to equity shareholders of the Company for the period amounted to RMB729 million, an increase of 0.3% compared with the corresponding period in 2020. • Profit for the period was RMB1,025 million, representing an increase of 30.4% compared with the corresponding period in 2020. • Net profit margin for the period was 5.0%, a decrease of 1.0 percentage point compared with 6.0% for the corresponding period in 2020. • Basic earnings per share for the period was RMB25.63 cents, a decrease of 3.0% compared with the corresponding period in 2020. • Declaration of an interim dividend of HK14.75 cents per share for the six months ended 30 June 2021. 1 INTERIM RESULTS The board (the “Board”) of directors (the “Directors” and each a “Director”) of Central China Real Estate
    [Show full text]
  • Working Papers the Rising Chinese Pharmaceutical
    Working papers The rising Chinese pharmaceutical industry: local champions vs global players Francesca Spigarelli Hao Wei ABSTRACT This paper is an exploratory study on main features and challenges of the Chinese pharmaceutical market. Dramatic changes in the market are due both to the Government policies, changing consumer habits and behaviour, and to the growing competition at firm level. From a demand side perspective, consumptions of pharmaceutical products are booming thanks to a combined effect of economic growth, aging population, urbanization and health system reforms. Key forces shaping the demand are examined in the chapter, with a specific attention to health care reforms as well as to new habits and confidence of Chinese people towards the Western medicine. In this regard, import and export trends, consumption, and expected evolution of the market are examined. From a supply side perspective, two main trends can be highlighted: the increasing interest of foreign investors, and the effort of Chinese pharmaceutical firms to compete in the national market. To better understand the ongoing changes we look at market characteristics, key players, as well as trends and motivation of inward FDI to China are examined. On the basis of this general picture, the paper focuses on IP related aspects, to understand who are the main actors of patenting trends (foreign vs local firms) and for which kind of products patents are registered (raw materials vs basic products vs drugs). Analyzing patent trends and the role of Chinese vs Western firms, we try to define how China is taking its role and position into the national and – potentially ‐ international pharmaceutical market.
    [Show full text]